Affiliations 

  • 1 Mechanical Engineering Discipline, School of Engineering, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, 47500, Malaysia
  • 2 Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, Bandar Sunway, Subang Jaya, Selangor, 47500, Malaysia
  • 3 MAHSA University, Jalan SP 2, Bandar Saujana Putra, Jenjarom, Selangor, 42610, Malaysia
Nanomedicine (Lond), 2022 Sep;17(21):1511-1528.
PMID: 36382634 DOI: 10.2217/nnm-2022-0017

Abstract

Background: Porous silicon (pSi) nanoparticles (NPs) functionalized with suitable targeting ligands are now established cancer bioimaging agents and drug-delivery platforms. With growing interest in peptides as tumor-targeting ligands, much work has focused on the use of various peptides in combination with pSi NPs for cancer theranostics. Here, the authors investigated the targeting potential of pSi NPs functionalized with two types of peptide, a linear 10-mer peptide and its branched (Y-shaped) equivalent, that respond to legumain activity in tumor cells. Results: In vitro experiments established that the linear peptide-pSi NP conjugate had better aqueous stability under tumor conditions and higher binding efficiency (p  0.05) of linear peptide-conjugated pSi NPs in the tumor site within 4 h compared with nonconjugated pSi NPs. These results suggest that the linear peptide-pSi NP formulation is a nontoxic, stable and efficient fluorescence bioimaging agent and potential drug-delivery platform.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.